Dynamic Changes of Torquetenovirus (TTV) Load in Chinese Renal Transplant Recipients

Launched by TONGJI HOSPITAL · Feb 5, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how levels of a virus called Torquetenovirus (TTV) change in patients who have received kidney transplants in China. The researchers want to find out if there is a connection between TTV levels and kidney transplant rejection or infections. They are also looking to see if changes in TTV levels can help predict these issues, which could improve care for kidney transplant recipients.

To participate in the trial, you need to be receiving a compatible kidney transplant and be on specific medications to help prevent rejection. Participants will attend 13 follow-up visits over a year, where they will provide small blood samples for testing TTV levels, along with other important tests. This study is currently recruiting participants aged 18 and older, and it is important to note that those with certain liver infections or receiving multiple organ transplants are not eligible. Overall, this trial aims to enhance understanding of how TTV may affect kidney transplant outcomes, which could lead to better treatment strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Receiving ABO compatible renal allotransplantation from the initiation of the study to December 31, 2023
• • Receiving tacrolimus /mycophenolate mofetil(or mycophenolic acid)/prednisone as maintenance immunosuppression after renal transplantation
• • Receiving universal prophylaxis for CMV infection and PJP infection
• Exclusion Criteria:
• • Receiving combined liver-kidney, pancreas-kidney or heart-kidney transplantation
• • Recipients with active hepatitis B or hepatitis C infection
• • Recipients with anticipated irregular follow-up